6GJ.F Glaukos Corporation

Healthcare Health Care Equipment & Supplies Frankfurt Exchange
210.00 EUR
Close of Nov 11, 2026
75.00 220.00
Market cap
EUR 12.4B
P/E
-
P/B
19.45x
ROE
-6.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 6GJ.F undervalued?

Graham number

The Graham number of Glaukos Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Glaukos Corporation fundamental analysis

No fundamental analysis for Glaukos Corporation yet.

Glaukos Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Glaukos Corporation

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the…

Full company profile